Bharat Biotech's US partner to commercialise Covaxin in Mexico

/2 min read

ADVERTISEMENT

In addition to the US and Canada, Ocugen will also have the exclusive rights for supply and commercialisation of Covaxin in Mexico.
Bharat Biotech's US partner to commercialise Covaxin in Mexico
Bharat Biotech has suspended the production of Covaxin for exports due to temporary slowing down of production. Credits: Sanjay Rawat

Bharat Biotech International Ltd (BBIL) has expanded the scope of its co-development, supply and commercialisation partnership for its Covid-19 vaccine Covaxin with US-based Ocugen Inc. In addition to the US and Canada, Ocugen will also have the exclusive rights for supply and commercialisation of Covaxin in Mexico, thus becoming the exclusive development and marketing partner of BBIL for the entire North America. BBIL said the vaccine continues to be under the WHO Emergency Use Listing (EUL).

However, the supply of Covaxin to these countries will not happen immediately as BBIL has suspended the production of Covaxin for exports due to temporary slowing down of production of Covaxin across its manufacturing facilities to focus on pending facility maintenance, process and facility optimisation activities.

Ocugen said that Covaxin is currently under review by Mexico's COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) for emergency use among children between 2 and 18 years of age.

Fortune India Latest Edition is Out Now!
India's Top 100 Billionaires

August 2025

As India continues to be the world’s fastest-growing major economy, Fortune India presents its special issue on the nation’s Top 100 Billionaires. Curated in partnership with Waterfield Advisors, this year’s list reflects a slight decline in the number of dollar billionaires—from 185 to 182—even as the entry threshold for the Top 100 rose to ₹24,283 crore, up from ₹22,739 crore last year. From stalwarts like Mukesh Ambani, Gautam Adani, and the Mistry family, who continue to lead the list, to major gainers such as Sunil Mittal and Kumar Mangalam Birla, the issue goes beyond the numbers to explore the resilience, ambition, and strategic foresight that define India’s wealth creators. Read their compelling stories in the latest issue of Fortune India. On stands now.

Read Now

The suspension of Covaxin exports was in response to the outcome of a WHO (World Health Organisation) inspection on 14–22 March 2022, which identified deficiencies in good manufacturing practices (GMP) at BBIL's Covaxin production units. Following the WHO observation, the U.S. Food and Drug Administration (FDA) had put the Covaxin clinical trial – the Phase 2/3 immuno-bridging and broadening study for Covaxin – carried out by Ocugen in the US on hold.

In an earlier statement, BBIL had said that since all of its existing facilities were repurposed for the manufacture of Covaxin, and with continuous production during the past year, to meet the public health emergency of Covid-19, these upgrades (of production facilities) were due. "Certain highly sophisticated equipment which were required to enhance the process stringency were unavailable during the Covid-19 pandemic. It has to be stressed that the quality of Covaxin was never compromised at any point in time," the company had said.

The statement had also pointed out that during WHO's inspection, Bharat Biotech agreed with the WHO team on the scope of the planned improvement activities and indicated that they will be executed as soon as practical.

On its part, the WHO had stated that the risk assessment to date does not indicate changes in the risk–benefit ratio. The data, available to WHO, indicate the vaccine is effective and no safety concerns exist. "Bharat Biotech has committed to addressing the GMP deficiencies and is developing a corrective and preventive action plan for submission to the Drugs Controller General of India (DCGI) and WHO. In the interim and as a precautionary measure, the company has indicated that it will suspend production of Covaxin for export. As a consequence, supply will be interrupted for the foreseeable future," the WHO statement said.

Fortune India is now on WhatsApp! Get the latest updates from the world of business and economy delivered straight to your phone. Subscribe now.